![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Versarien Plc | LSE:VRS | London | Ordinary Share | GB00B8YZTJ80 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.108 | 0.1005 | 0.1195 | - | 6,026,970 | 08:00:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 5.45M | -13.53M | -0.0091 | -0.12 | 1.61M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/8/2018 12:06 | Can only sell 25k lumps AM, at 154.5pBut that's better than 9.30, when I fell back asleep! | ![]() festario | |
24/8/2018 12:05 | It may be worth remembering that ground zero will shift when one or more new institutional investors appear on the VRS scene. It is entirely possible when/if some RNS's are published showing new institutional holders, apart from the share price shifting a gear up, a new baseline for the share price will be established. At that juncture, it would be perfectly reasonable to expect at least a doubling of the share price. For this reason, and the newsflow, and the amazing potential of VRS, I will not be selling. I remain a relaxed and sanguine long term holder. | ![]() turbocharge | |
24/8/2018 12:05 | I see Diplomat65 has had to send for backup ;-) | ![]() grabster | |
24/8/2018 12:04 | What are the numbers looking like Fest? | ![]() andymoore07 | |
24/8/2018 12:03 | 🍌 # ITS BANANA TIME! # 🍌 | cdub1 | |
24/8/2018 12:03 | Why the pop at Fhasson? | ![]() festario | |
24/8/2018 12:00 | Nice to see that Graham Stuart was also with Liam Fox. | ![]() rogerbridge | |
24/8/2018 11:59 | ffahson one word idiot!! | ![]() ratpat999 | |
24/8/2018 11:59 | >>>Diplomat In fact Nanene is functionalised, it contains up to 2% oxygen and this is most certainly due to the oxygen containing functional groups at the terminal carbon atoms. This is why it can be dispersed in certain composites, if it did not have this functionalisartion, the dispersion properties would undoubtedly be poor | ![]() timbo003 | |
24/8/2018 11:58 | Ray to replace NR unfortunately CS. | ![]() sonsonnyjim | |
24/8/2018 11:57 | Fhasson lol | ![]() chimpandy1 | |
24/8/2018 11:56 | Fyffes, is what's going on | ![]() pandar | |
24/8/2018 11:55 | VRS is being taken over by Haydale | ![]() fhasson | |
24/8/2018 11:54 | I think it’s VRS welcome to the world time :) | ![]() haz101 | |
24/8/2018 11:53 | I'm dreading a takeover approach. Don't care how astronomical a price someone pays now, will look a pittance in years to come. YouTube sold for $1.6bn in 2006? Looks like an absolute steal... | ![]() club sandwich | |
24/8/2018 11:51 | I'm awake now. What's going on? | ![]() festario | |
24/8/2018 11:47 | Lucky - was it you who said no poddy today (or any one) were did that info' come from? Best wishes - spike | ![]() spike_1 | |
24/8/2018 11:45 | Looks like some of the AECOM team are coming to the investor golf day! I look forward to chatting with them along with hopefully meeting a few more on this board/twitter :) | ![]() a_game | |
24/8/2018 11:40 | Fellow shareholders as Neill has said several times and live to us at the investor day don’t speculate about the properties of nanene / any of their business if you don’t know 100% ask Neill privately by email 1st !! | ![]() ratpat999 | |
24/8/2018 11:39 | And anyway - (Diplomat65 post 28913) - Haydale (and several others) offer a functionalising facility, to which Versarien have access if they want. (They have worked together before) So any story that NR is "desperate" to have such options is total nonsense. He already has them. | ![]() grabster | |
24/8/2018 11:38 | 160 today anyone? | ![]() pshevlin | |
24/8/2018 11:37 | Liar they are homeless thanks to his shorting he's living in a tent | ![]() borg45 | |
24/8/2018 11:31 | Diplomat re functionalization. It's a bit semantic but some thoughts on the subject. Somewhere in my research I came across Graphene made from very very pure Graphite. The graphite had no functional groups attached. When that graphite was used to make Graphene the resulting product was difficult to formulate in composites as it had no chemical groups attached. It could be made to work by adding functional groups but as sg says this can damage the resulting Graphene so care must be taken. Now if you look at Nanene it's 98% carbon +/- 1%. There's a small quantity of oxygen, nitrogen, sulphur etc. We know Nanene can in many cases be blended into composites without further functionalization. My assumption is that the very small non carbon element in Nanene is sufficient 'functionalization' to allow it to be dispersed. As I say it's semantics but you could say Nanene is functionalised and doesn't need further action. 100% pure Graphene probably needs functionalising but that would be a very rare material. I agree with sg that using a blank statement that all Graphene needs functionalizing is inaccurate. | ![]() serratia | |
24/8/2018 11:20 | Interesting story "It could take 10 years before the new treatment comes to market" "bought for £623 million" News story Published 23 August 2018 Bristol pharmaceuticals startup bought for £623 million University spin-out - supported by UK Research and Innovation funding - acquired to develop 'groundbreaking' treatment for diabetes. Ziylo has been bought in a £623 million deal by Novo Nordisk, the biggest maker of diabetes drugs in the world. Effective and safe management of diabetes The company - which was spun out of the University of Bristol 4 years ago - has pioneered a synthetic molecule that binds glucose in the bloodstream more effectively in the treatment of diabetes. It comes out of 20 years of research at the university. This module could eliminate the risk of hypoglycaemia, where blood sugar falls below normal levels. Hypoglycaemia is the main risk to those using insulin therapy and can be dangerous if not treated properly, leading to seizures or coma. With the acquisition, Novo Nordisk hopes to use the module to develop a new kind of insulin so that people with diabetes can manage their condition more safely. It could take 10 years before the new treatment comes to market, with the £623 million deal staged based on the potential success of the treatment. Research supported by Innovate UK and EPSRC Ziylo was founded by Professor Anthony Davis, PHD student Dr Harry Destecroix and businessman Tom Smart. The team has received various research and innovation support over the years to help translate their academic thinking into commercial application. They went through the Innovation and Commercialisation of University Research (ICURe) programme, which helps university researchers explore the commercial potential of their idea, and were awarded £500,000 by Innovate UK to set up Ziylo. Professor Davis - a supervisor at the Engineering and Physical Sciences Research Council’s Centre for Doctoral Training in Chemical Synthesis - has also been supported long-term by the council with 3 awards for his research. Dr Harry Destecroix, Chief Executive and co-founder of Ziylo, said: Novo Nordisk is the ideal company to maximise the potential of the Ziylo glucose binding molecules in glucose responsive insulins and diabetes applications. It brings hope of a truly groundbreaking treatment to diabetes patients. | ![]() curtain twitcher |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions